Product information and disease descriptionProduct descriptionProduct information
Drug/Drug, drug/disease interactions
10 evidence topics · 12 sources
RP-A501 (AAV9.LAMP2B)
Danon disease
- Manufacturer
- Rocket Pharmaceuticals
- Regulatory submission
- BLA planned for late 2028
- Launch
- Anticipated in mid-2029
- Last updated